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Essentials
• FccRIIa mediates life-threatening heparin-induced
thrombocytopenia (HIT).
• Most anti-platelet factor (PF)4-heparin IgGs are not
pathogenic so diagnosis of HIT is challenging.
• Dimeric rsFccRIIa was used to quantify receptor-bind-
ing activity of anti-PF4-heparin antibodies.
• Dimeric rsFccRIIa binding specifically correlated with
occurrence of HIT.
Summary. Background: Heparin-induced thrombocytope-
nia (HIT) is a major and potentially fatal consequence of
antibodies produced against platelet factor 4 (PF4)–hep-
arin complexes following heparin exposure. Not all anti-
PF4–heparin antibodies are pathogenic, so overdiagnosis
can occur, with resulting inappropriate use of alternative
anticoagulation therapies that have associated risks of
bleeding. However, definitive platelet functional assays are
not widely available for routine analysis. Objectives: To
assess the utility of dimeric recombinant soluble FccRIIa
(rsFccRIIa) ectodomains for detecting HIT antibod-
ies. Patients/Methods: Plasma from 27 suspected HIT
patients were tested for pathogenic anti-PF4–heparin
antibodies by binding of a novel dimeric FccRIIa ectodo-
main probe. Plasmas were also tested by the use of PF4–
heparin IgG ELISA, the HemosIL AcuStar HIT IgG-spe-
cific assay, and a serotonin release assay (SRA). Results:
The dimeric rsFccRIIa test produced no false positives
and excluded four samples that were positive by IgG
ELISA. In this small patient cohort, the novel assay cor-
rectly assigned 93% of the suspected HIT patients, with
two of the HIT patients being scored as false negatives.
The improved discrimination of the novel assay over the
IgG ELISA, which scored four false positives, supports
the mechanistic interpretation that binding of dimeric
rsFccRIIa detects pairs of closely spaced IgG antibodies
in PF4–heparin immune complexes. Conclusions: This
study found the cell-free, function-based dimeric
rsFccRIIa assay to be convenient, simple, and potentially
predictive of HIT. The assay had improved specificity over
the IgG ELISA, and correlated strongly with the AcuStar
HIT IgG-specific assay, warranting further evaluation of
its potential to identify HIT in larger patient cohorts.
Keywords: enzyme immunoassay; heparin; platelet factor
4; thrombocytopenia; thrombosis.
Introduction
Heparin-induced thrombocytopenia (HIT) occurs when
antibodies form immune complexes (ICs) with platelet
factor 4 (PF4) bound to heparin or glycosaminoglycans
[1–3]. The pathogenic ICs bind to FccRIIa, which is the
only FccR on platelets, triggering their activation and
aggregation, leading to thrombosis. Binding to FccRIIa
on monocytes also causes both prothrombotic production
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of thrombin and tissue factor [4] and the clearance of pla-
telets and thrombocytopenia [5]. Many patients treated
with heparin develop antibodies against PF4–heparin, but
the presence of antibody–PF4–heparin complexes does
not necessarily result in clinical manifestations of throm-
bosis/thrombocytopenia. Antigen recognition-based meth-
ods (e.g. ELISA) detect anti-PF4–heparin antibodies, but
fail to distinguish pathogenic from non-pathogenic anti-
bodies. Thus, platelet functional assays, such as the sero-
tonin release assay (SRA), are the most reliable for
confirming HIT [2,6,7], but require access to appropriate
donor platelets that are sensitive to activation, and are
not easily replicated between many clinical laboratories.
The mAb KKO binds the PF4–heparin complex and
activates human platelets in an FccRIIa-dependent man-
ner [8]; it causes HIT in a human FccRIIa/PF4 transgenic
mouse model [9,10]. A recent X-ray crystallography anal-
ysis showed the KKO mAb bound to a conformation-
dependent epitope on heparin-related pentasaccharide
(fondaparinux)-bound PF4 tetramers, promoting the for-
mation of higher-order complexes [11,12]. In contrast, a
non-pathogenic antibody bound an overlapping epitope,
but only in the PF4 monomer. Plate-based ELISAs pre-
sent a heterogeneous mixture of PF4 forms, and so do
not distinguish innocuous antibodies from those forming
complexes capable of activating FccRs.
Pathological HIT antibodies engage FccRIIa, and trig-
ger platelet activation and clearance [3] and tissue factor
production [4]. The pathology depends, in part, on an
R131H polymorphism within FccRIIa, which does not
alter the expression levels of the receptor but does signifi-
cantly alter the affinity of FccRIIa for its ligand [13]. We
recently described the use of dimeric recombinant soluble
FccRIIa (rsFccRIIa) to determine the proximity of pairs
of IgG antibodies in immune cell-activating ICs [14]. The
binding of dimeric rsFccRIIa in this assay is correlated
with the capacity of IgG ICs to activate FccR-dependent
cellular responses [14,15]. In this study, we tested the
capacity of this unique dimeric rsFccRIIa to distinguish
pathogenic antibodies, which recognize PF4–heparin com-
plexes and are able to activate platelets, from clinically
irrelevant, non-pathogenic antibodies.
Materials and methods
Plasma samples were obtained from 27 medical and surgi-
cal inpatients based at a tertiary hospital, the Royal Ade-
laide Hospital, in Adelaide, Australia, in whom HIT was
suspected. Local ethics committee approval was obtained
prior to the commencement of the study. The collection
of samples conformed to institutional guidelines. Both
plasma from citrated blood and sera were prepared for
analysis. For the purposes of this study, and to ensure
that HIT cases reflected the integration of both clinical
and laboratory criteria, a diagnosis of HIT was defined as
a 4T score of ≥ 4 and a positive SRA result (> 20% at
0.1 U mL1 heparin, and suppression at 100 U mL1
heparin) [16]. Levels of PF4–heparin autoantibodies were
analyzed with an IgG-specific solid-phase ELISA (GTI,
Waukesha, WI, USA) [17] and with the HemosIL AcuS-
tar HIT IgG-specific assay (Instrumentation Laboratory,
Bedford, MA, USA) [18] under standardized laboratory
conditions. High specificity with the HemosIL AcuStar
HIT IgG-specific assay has been previously reported [17].
The production and use of dimeric rsFccRIIa (His131
allelic form) has been described previously [14]. To assess
the ability of dimeric rsFccRIIa to differentially bind
pathogenic versus non-pathogenic HIT antibodies, patient
plasma was used in a PF4–heparin IgG ELISA kit (Diag-
nostica Stago, Melbourne, Victoria, Australia) at a plasma
dilution of 1 : 40, and with incubation and washing steps
according to the manufacturers’ instructions. The bound
anti-PF4–heparin antibodies were then reacted with
dimeric rsFccRIIa–biotin (0.2 lg mL1) in phosphate-
buffered saline (PBS) diluent containing 1 mM EDTA,
0.05% (v/v) Tween-20 and 1% (w/v) bovine serum albu-
min for 1 h at 37 °C, and this was followed by five cycles
of filling and aspirating wells with wash buffer (PBS,
0.05% v/v Tween-20). Bound receptor was then detected
by the incubation with a 1 : 10 000 dilution of high-sensi-
tivity horseradish peroxidase–streptavidin (Pierce, Rock-
ford, IL, USA), for 1 h at 37 °C, washed 10 times, and
incubated with TMB Single solution (Life Technologies,
Mulgrave, Victoria, Australia). The reaction was termi-
nated with an equal volume of 1 M HCl, and absorbance
at 450 nm was determined. An in-house plasma sample
from a patient with confirmed HIT (4T score of 8, an
SRA release of 94.2% with suppression of serotonin
release with high-dose heparin, and an anti-heparin–PF4
antibody OD of > 3.0 by IgG ELISA) was used as a stan-
dard to define a nominal 100% response, to which absor-
bance values were normalized.
Statistical analysis was performed with GRAPHPAD PRISM
version 6.05 (GraphPad Software, San Diego, CA, USA).
The optimal OD cut-off for the dimeric rsFccRIIa assay
(normalized value = 3) was confirmed by receiver operat-
ing characteristic analysis (not shown). Cut-off values for
the PF4–heparin IgG ELISA (OD = 0.4) and for the
HemosIL AcuStar HIT IgG-specific assay (1 U mL1)
were defined according to the manufacturers’ instructions.
SRA positivity was defined as > 20% serotonin release
with low-dose heparin at 0.1 U mL1, and < 20% release
with a high heparin concentration of 100 U mL1.
Results and discussion
A cohort of 27 patients with suspected HIT were evalu-
ated, of whom 13 were considered to be HIT-positive
because of a positive SRA finding and a 4Ts score of ≥ 4
[6]. Samples were also evaluated for anti-PF4–heparin
antibodies with PF4–heparin IgG ELISA and the Hemo-
sIL AcuStar HIT IgG-specific assay. The ability of a
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novel engineered dimeric rsFccRIIa (His131) to detect
pathogenic anti-PF4–heparin antibodies was evaluated by
comparison with these established assays.
The novel dimeric rsFccRIIa assay, AcuStar HIT IgG-
specific assay and PF4–heparin IgG ELISA all showed
significantly higher mean activity for HIT-positive sam-
ples than for HIT-negative samples (all assays, Mann–
Whitney U-test P < 0.0001; Figure 1A). The performance
of the assays in distinguishing HIT patients is
summarized in Table 1. The dimeric rsFccRIIa assay cor-
rectly assigned 93% of the patients (25/27) and did not
detect two HIT samples (i.e. two false negatives). This
was similar to the performance of the AcuStar HIT IgG-
specific assay, which correctly assigned 96%, with only
one false negative. These two assays contrasted with the
more sensitive PF4–heparin IgG ELISA, which had a
lower specificity (71%), with four false positives from this
cohort. Larger patient groups that include differing clini-
cal groupings will be necessary to establish robustly the
predictive value of this approach.
A comparison of the dimeric rsFccRIIa and AcuStar
HIT IgG-specific assays for the HIT-positive samples
showed that these two assays correlated more strongly
with each other (Spearman’s correlation r = 0.845,
P = 0.0005) than either did with the PF4–heparin IgG
ELISA (ELISA versus AcuStar assay, r = 0.813,
P = 0.0015; ELISA versus dimeric rsFccRIIa assay,
r = 0.673, P = 0.015).
As the SRA is a definitive functional assay for the diag-
nosis of HIT, and the main limitation of the PF4–heparin
IgG ELISA is that it gives false positives, we examined
the samples that were positive with the PF4–heparin IgG
ELISA (Figure 2A) and the relationship between their
activities in the SRA and in the other assays (Figure 2B,
C). Both the AcuStar HIT IgG-specific and dimeric
rsFccRIIa assays appropriately assigned low, below cut-
off, values to the SRA-negative samples, although some
were very near the cut-off values of both assays. Further-
more, the AcuStar HIT IgG-specific and dimeric
rsFccRIIa assays also correctly assigned as negative a
sample (see filled blue star; Figure 2) that had ~ 50%
release at both high and low heparin doses, and was
weakly positive with the PF4–heparin IgG ELISA. The
AcuStar HIT IgG-specific and dimeric rsFccRIIa assays,
although correlating strongly (Figure 1B), showed some
important differences (Figure 2B,C). One HIT patient
plasma sample was weakly AcuStar HIT IgG-specific
assay-positive (1.78 U mL1; cut-off of 1.0 U mL1) and
dimeric rsFccRIIa assay-negative (0.4% response; cut-off
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Fig. 1. Comparison of the novel dimeric recombinant soluble
FccRIIa (rsFccRIIa) assay with existing serological assays for the
detection of heparin-induced thrombocytopenia (HIT) antibodies.
(A) Suspected HIT patients were segregated on the basis of a posi-
tive serotonin release assay (SRA) result and a 4Ts score of ≥ 4. The
three dashed lines indicate the cut-off values for a positive result
with each assay. These thresholds were 3% of the normalized signal
for the dimeric rsFccRIIa assay: 1 U mL1 for the AcuStar HIT
IgG-specific assay, and an OD of 0.4 (right y-axis) for the platelet
factor 4 (PF4)–heparin IgG ELISA. Two sets of parentheses mark
the false negatives from the assays: two from the dimeric rsFccRIIa
assay, and one from the AcuStar HIT IgG-specific assay. The third
set of parentheses marks the four false positives from the PF4–hep-
arin IgG ELISA. (B) The dimeric rsFccRIIa and AcuStar HIT IgG-
specific assays were correlated for the HIT-positive (i.e. 4T score of
≥ 4 and SRA-positive) samples. Cut-off values for the two assays are
shown as dotted and dashed lines, respectively. HIT samples with
low antibody levels are more sensitively identified by combining both
the dimeric rsFccRIIa and AcuStar HIT IgG-specific assays. When
HIT positivity is defined as rsFccRII a positivity and/or AcuStar
HIT IgG-specific assay positivity, sensitivity is improved over that
with either assay used alone.
Table 1 Immunoassays of patient plasma (n = 27) with or without
heparin-induced thrombocytopenia (HIT) defined by a positive sero-
tonin release assay result and a 4Ts score of ≥ 4
Assay
Positive test
Negative
test
Specificity SensitivityTrue False True False
Dimeric
rsFccRIIa
11 0 14 2 1.00 0.85
PF4–heparin
IgG
13 4 10 0 0.71 1.00
AcuStar HIT
IgG-specific
12 0 14 1 1.00 0.92
PF4, platelet factor 4; rsFccRIIa, recombinant soluble FccRIIa.
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of 3%; open triangle, Figure 2). Another HIT patient
was weakly positive with the AcuStar HIT IgG-specific
assay (1.05 U mL1) but scored strongly in the dimeric
rsFccRIIa assay (67% response; open square, Figure 2).
Thus, defining samples as HIT-positive according to
AcuStar HIT IgG-specific assay-positive and/or dimeric
rsFccRIIa assay-positive criteria may be an approach for
improving HIT prediction with either assay alone.
In HIT, pathogenic PF4–heparin IgG complexes
engage and aggregate FccRIIa on platelets [1,3,5], and
possibly other FccRs on monocytes [4,19]. The size and
stoichiometry of IgG ICs are major determinants of both
the avidity of interaction with the low-affinity FccRs [20]
and the capacity of anti-PF4–heparin antibodies to acti-
vate cells. In a large proportion of laboratories, the initial
clinical suspicion of HIT is followed by the performance
of standard HIT IgG ELISAs. However, the diagnosis of
HIT and subsequent decisions regarding patient anticoag-
ulation and management are made challenging by the
prevalence of non-pathogenic anti-PF4–heparin antibod-
ies that are unable to activate FccRs. Although the levels
of anti-PF4–heparin antibodies as detected by HIT IgG
ELISA provide useful information, this measurement
alone does not provide sufficient specificity for the diag-
nosis of HIT [7,21].
Thus, a platelet functional HIT assay, such as platelet
aggregation or the SRA, is crucial for diagnosis. The
SRA, however, involves handling of radioactive isotopes
and requires specialized personnel, specialized equipment
and rapid access to functional ‘high-responder’ platelets
that may not be routinely available. Use of the SRA is
also limited to major reference laboratories. Refinements
to improve the specificity of the HIT anti-PF4–heparin
antibody ELISA have included raising the OD cut-off for
positive results and the addition of a high-dose heparin
confirmatory step [16,22]. However, there is still a need
for improved serological HIT assays.
We investigated the potential of dimeric rsFccRIIa, a
probe of the FccR-mediated effector functionality of IgG
complexes, to improve the specificity of a PF4–heparin
IgG assay. The novel assay had superior specificity to the
detection of PF4–heparin IgG by ELISA, and performed
similarly to the HemosIL AcuStar HIT IgG-specific
assay, a test in which high specificity has been reported
previously [18]. The combined use of both the dimeric
rsFccRIIa and HemosIL AcuStar HIT IgG-specific assays
to assign HIT correctly identified some HIT samples that
would have been false negative with the use of either
assay alone. The detection of HIT antibodies with the
dimeric rsFccRIIa assay adds a functional qualitative
component to the assay that mechanistically underlies the
possible improved specificity and utility.
Dimeric rsFccRIIa binding requires closely spaced
pairs of antibodies, as occurs in ICs [14], and has been
used to detect FccR functional antibodies against influ-
enza virus and HIV envelope proteins [14,15,23–28]. HIT
pathogenesis requires Fc-mediated clustering of platelet
FccRIIa, but two SRA-positive samples were not detected
with the dimeric rsFccRIIa-binding assay. Studies of
HIT complexes have shown that the formation of the
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Fig. 2. Correlation of the novel dimeric recombinant soluble
FccRIIa (rsFccRIIa) assay and the existing serological assays with
serotonin release. Results from all the serological assays of samples
positive in the IgG ELISA, including four HIT false positives (filled
blue star and black circles), were compared against the SRA results.
The SRA (release at 0.1 U mL1 heparin) was compared with (A)
the PF4–heparin IgG ELISA, (B) the AcuStar HIT IgG-specific
assay, and (C) the novel dimeric rsFccRIIa assay. The dashed lines
indicate the cut-off values for a positive result with each assay. Open
symbols represent HIT-diagnosed patients (positive SRA result and
a 4Ts score of ≥ 4). Filled symbols represent PF4–heparin IgG
ELISA-positive HIT-negative patients, with the blue star symbol
indicating one SRA-negative patient with equivalent levels of sero-
tonin release with both high-dose and low-dose heparin stimulation.
The open triangle indicates an HIT patient plasma sample that was
weakly AcuStar HIT IgG-specific assay-positive and dimeric
rsFccRIIa assay-negative, and the open square indicates an HIT
patient plasma sample that was weakly AcuStar HIT IgG-specific
assay-positive and strongly dimeric rsFccRIIa assay-positive. [Color
figure can be viewed at wileyonlinelibrary.com]
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PF4–heparin–IgG complex is dynamic and, importantly,
the proximity of the IgG Fcs in the pathogenic complexes
is influenced by the binding of heparin, and the epitope
specificity and avidity of the bound IgG [11,12,29,30].
The failure of the dimeric rsFccRIIa assay to detect these
two HIT samples suggests that the Fcs were not appropri-
ately presented in the current ELISA format. Thus, the
assay may need further optimization to a format that
mimics the dynamic behavior of the PF4 complexes that
cluster platelet FccRIIa in vivo. Nonetheless, our proof-
of-concept study has shown that the dimeric rsFccRIIa
assay has the potential to be predictive of HIT and war-
rants further investigation.
This study has established a novel FccRIIa probe as a
powerful surrogate for evaluating HIT antibody function-
ality. The use of dimeric rsFccRIIa also offers the advan-
tages that it is simple, scalable, and adaptable to any
format, such as multiplexing [25] and flow cytometry.
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